The European Commission has cleared Revolution Medicines’ daraxonrasib for adults with metastatic pancreatic cancer following at least one prior systemic treatment, opening a new treatment option for patients across the EU.
The approval covers patients with metastatic pancreatic adenocarcinoma, regardless of whether they have an identified RAS tumour mutation. The drug is administered orally once daily in tablet form.
The decision brings a new treatment option to patients facing a disease for which therapeutic choices have historically been limited, particularly after initial treatment.
“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches,” said Thomas Seufferlein, medical director, Clinic for Internal Medicine I, Ulm University Hospital.
“The European Commission’s approval of daraxonrasib represents an important advance for patients with this aggressive and difficult-to-treat disease. The unprecedented survival benefit demonstrated in the RASolute 302 clinical trial underscores the potential of daraxonrasib to establish a new standard of care for eligible patients with metastatic pancreatic cancer across the European Union.”
Revolution Medicines described the European approval as a pivotal milestone in its efforts to expand access to the treatment.
“Today’s European Commission approval of RASONQUE represents a pivotal moment for people in the European Union living with metastatic pancreatic cancer, as well as their families,” said Mark A. Goldsmith, chief executive officer and chairman of Revolution Medicines.
“With RASONQUE now approved, we are actively working with healthcare systems and stakeholders across the region to support timely access for eligible patients. We also continue to engage with regulatory authorities around the world with the goal of expanding and accelerating the reach of RASONQUE to patients who may benefit from it.”
The European Commission's decision follows a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The drug underwent an expedited, phased review under the EMA’s Cancer Medicines Pathfinder project, reflecting its potential to address a significant unmet medical need.
The approval is backed by results from the Phase 3 RASolute 302 clinical trial, presented at the 2026 American Society of Clinical Oncology Annual Meeting and simultaneously published in The New England Journal of Medicine.
The global, randomised trial compared RASONQUE with investigator-selected cytotoxic chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
The study met all primary and key secondary endpoints in both the RAS G12 mutant patient population and the overall intent-to-treat (ITT) population, which included patients with and without an identified tumour RAS mutation.